Targeted therapies for ER+/HER2- metastatic breast cancer

Abstract excerpt

The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine resistance, either primary or secondary, remains an important issue in this type of tumor. The improvement of our...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Cancer Treatment and Pharmacology
• Share to HER2/EGFR in Cancer Research